Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and autoimmune disorders.


Updates from The Motley Fool

Latest updates on Pluristem Therapeutics from Fool.com.
This Week in Biotech: Part 2

A look at the biggest stories this week in biotech and what they mean for investors.

The Stocks Wall Street Loves

Analysts are unanimously bullish, but do you agree with these Wall Street darlings?



Stock Performance

View Interactive PSTI Charts
Sponsored by

Key Data Points

Primary metrics and data points about Pluristem Therapeutics.
Current Price: $1.37
Prev Close: $1.35
Open: $1.34
Bid: $1.36
Ask: $1.38
Day's Range: $1.25 - $1.37
52wk Range: $1.04 - $1.85
Volume: 261,681
Avg Vol 134,682
Market Cap: $132M
P/E (ttm): -4.09
EPS (ttm): ($0.33)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Pluristem Therapeutics.
CAPS Rating 1 out of 5
 
45 Outperform
20 Underperform
CAPS All Stars
 
2 Outperform
12 Underperform

How do you think Pluristem Therapeutics will perform against the market?



You pick for Pluristem Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Zami Aberman, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Pluristem Therapeutics.

Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and autoimmune disorders.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers